Scleroderma Diagnostics and Therapeutics Market
Global Scleroderma Diagnostics and Therapeutics Market: Snapshot
The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.
According to Transparency Market Research, the global scleroderma diagnostics and therapeutics market was valued at US$1,689.7 mn in 2017 and is projected to expand at a CAGR of 10.3% from 2017 to 2024 to reach US$3,663.8 mn by 2024.
Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category
Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.
It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.
Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed a significant share of the global scleroderma therapeutics market in the recent past; however, the share of this segment is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.
Developed Regions to Continue to Command Dominance
Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America and Europe held significant share of the global scleroderma therapeutics market in the recent past. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.
The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting significant CAGR over the period between 2017 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.
Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.
Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.
The global scleroderma diagnostics and therapeutics market was worth US$1,689.7 mn and is projected to reach a value of US$3,663.8 mn by the end of 2024
Scleroderma diagnostics and therapeutics market is anticipated to grow at a CAGR of 10.3% during the forecast period
North America and Europe accounted for a major share of the global scleroderma diagnostics and therapeutics market
Scleroderma Diagnostics And Therapeutics Market is driven by increasing focus globally on treatment of orphan diseases and advancements in the field of rheumatoid treatments
Key players in the global scleroderma diagnostics and therapeutics market include Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2014–2024
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials
Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
5.3.1. Localized
5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2015
5.5. Key Trends and Developments
Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Agents
6.3.3. Endothelin receptor antagonists
6.3.4. Calcium Channel Blockers
6.3.5. PDE-5 Inhibitors
6.3.6. Chelating Agents
6.3.7. Prostacyclin analogues
6.3.8. Others
6.4. Market Attractiveness Analysis, by Drug Class, 2015
6.5. Key Trends and Developments
Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2015
7.5. Key Trends
Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication
8.3.1. Localized
8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
8.4.1. Corticosteroids
8.4.2. Immunosuppressive Agents
8.4.3. Endothelin receptor antagonists
8.4.4. Calcium Channel Blockers
8.4.5. PDE-5 Inhibitors
8.4.6. Chelating Agents
8.4.7. Prostacyclin analogues
8.4.8. Others
8.5. Market Size (US$ Mn) Forecast, by Country
8.5.1. U.S.
8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Market Attractiveness Analysis, by Drug Class, 2015
8.8. Key Trends
Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
9.3.1. Localized
9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
9.4.1. Corticosteroids
9.4.2. Immunosuppressive Agents
9.4.3. Endothelin receptor antagonists
9.4.4. Calcium Channel Blockers
9.4.5. PDE-5 Inhibitors
9.4.6. Chelating Agents
9.4.7. Prostacyclin analogues
9.4.8. Others
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.K.
9.5.2. Germany
9.5.3. France
9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2015
9.7. Market Attractiveness Analysis, by Drug Class, 2015
9.8. Key Trends
Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Indication
10.3.1. Localized
10.3.2. Systemic
10.4. Market Size (US$ Mn) Forecast, by Drug Class
10.4.1. Corticosteroids
10.4.2. Immunosuppressive Agents
10.4.3. Endothelin receptor antagonists
10.4.4. Calcium Channel Blockers
10.4.5. PDE-5 Inhibitors
10.4.6. Chelating Agents
10.4.7. Prostacyclin analogues
10.4.8. Others
10.5. Market Size (US$ Mn) Forecast, by Country
10.5.1. China
10.5.2. India
10.5.3. Japan
10.5.4. Rest of Asia Pacific
10.6. Market Attractiveness Analysis, by Indication, 2015
10.7. Market Attractiveness Analysis, by Drug Class, 2015
10.8. Key Trends
Chapter 11. Latin America Scleroderma Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product
11.3.1. Localized
11.3.2. Systemic
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
11.4.1. Corticosteroids
11.4.2. Immunosuppressive Agents
11.4.3. Endothelin receptor antagonists
11.4.4. Calcium Channel Blockers
11.4.5. PDE-5 Inhibitors
11.4.6. Chelating Agents
11.4.7. Prostacyclin analogues
11.4.8. Others
11.5. Market Size (US$ Mn) Forecast, by Country
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis, by Indication, 2015
11.7. Market Attractiveness Analysis, by Drug Class, 2015
11.8. Key Trends
Chapter 12. Middle East & Africa Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Indication
12.3.1. Localized
12.3.2. Systemic
12.4. Market Size (US$ Mn) Forecast, by Drug Class
12.4.1. Corticosteroids
2.4.2. Immunosuppressive Agents
12.4.3. Endothelin receptor antagonists
12.4.4. Calcium Channel Blockers
12.4.5. PDE-5 Inhibitors
12.4.6. Chelating Agents
12.4.7. Prostacyclin analogues
12.4.8. Others
12.5. Market Size (US$ Mn) Forecast, by Country
12.5.1. UAE
12.5.2. South Africa
12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis, by Indication, 2015
12.7. Market Attractiveness Analysis, by Drug Class, 2015
12.8. Key Trends
Chapter 13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
13.2.1. Actelion Pharmaceuticals, Inc.
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Financial Overview
13.2.1.3. Product Portfolio
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Bayer AG
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Financial Overview
13.2.2.3. Product Portfolio
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. Boehringer Ingelheim
13.2.3.1. Company Overview (HQ, business segments, employee strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Financial Overview
13.2.3.5. Strategic Overview
13.2.4. Corbus Pharmaceutical Holdings, Inc.
13.2.4.1. Company Overview (HQ, business segments, employee strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Strategic Overview
13.2.4.5. Key Developments
13.2.5. Cumberland Pharmaceuticals Inc.
13.2.5.1. Company Overview (HQ, business segments, employee strength)
13.2.5.2. Financial Overview
13.2.5.3. Product Portfolio
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. Cytori Therapeutics, Inc.
13.2.6.1. Company Overview (HQ, business segments, employee strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Financial Overview
13.2.6.5. Strategic Overview
13.2.7. F. Hoffmann La Roche Ltd.
13.2.7.1. Company Overview (HQ, business segments, employee strength)
13.2.7.2. Financial Overview
13.2.7.3. Product Portfolio
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. Gilead Sciences, Inc.
13.2.8.1. Company Overview (HQ, business segments, employee strength)
13.2.8.2. Financial Overview
13.2.8.3. Product Portfolio
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Merck KGaA
13.2.9.1. Company Overview (HQ, business segments, employee strength)
13.2.9.2. Product Portfolio
13.2.9.3. Financial Overview
13.2.9.4. SWOT Analysis
13.2.9.5. Strategic Overview
13.2.10. Pfizer, Inc.
13.2.10.1. Company Overview (HQ, business segments, employee strength)
13.2.10.2. Product Portfolio
13.2.10.3. Financial Overview
13.2.10.4. SWOT Analysis
13.2.10.5. Strategic Overview
13.2.11. Sanofi
13.2.11.1. Company Overview (HQ, business segments, employee strength)
13.2.11.2. Product Portfolio
13.2.11.3. Financial Overview
13.2.11.4. SWOT Analysis
13.2.11.5. Strategic Overview
List of Tables
Table 1: Overview of active clinical trials for scleroderma
Table 2: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 3: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 4: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 5: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 6: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 7: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 8: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 9: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024s
Table 10: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 12: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 13: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 14: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 15: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 16: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 17: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 18: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 19: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 20: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 21: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 22: North America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 23: Europe Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 24: Asia Pacific Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 25: Latin America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 26: Middle East & Africa Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
List of Figures
Figure 1: Global Scleroderma Therapeutics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 2: Global Scleroderma Diagnostics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 3: Scleroderma Therapeutics Market Value Share by Drug Class (2016)
Figure 4: Scleroderma Therapeutics Market Value Share by Indication (2016)
Figure 5: Scleroderma Therapeutics Market Value Share by Region (2016)
Figure 6: Scleroderma Diagnostics Market Value Share by Test Type (2016)
Figure 7: Global Scleroderma Therapeutics Market Value Share Analysis, by Indication Type, 2016 and 2024
Figure 8: Global Localized Scleroderma Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 9: Global Systemic Scleroderma Market Revenue US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 10: Scleroderma Therapeutics Market Attractiveness Analysis, by Indication Type, 2015
Figure 11: Global Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 12: Global Corticosteroids Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 13: Global Immunosuppressive Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 14: Global Endothelin Receptor Agonists Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 15: Global Calcium Channel Blockers Market Revenue ((US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 16: Global PDE-5 Inhibitors Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 17: Global Chelating Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 18: Global Prostacyclin Analogs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 19: Global Other Scleroderma Drugs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
Figure 20: Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 21: Global Scleroderma Therapeutics Market Value Share Analysis, by Region, 2016 and 2024
Figure 22: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015
Figure 23: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 24: North America Scleroderma Therapeutics Market Size and Y-o-Y Growth Projections, 2015–2024
Figure 25: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 26: North America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 27: North America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 26: highlights the estimated and forecast market value share of the drug class segments for 2016 and 2014
Figure 28: North America Scleroderma Therapeutics Market Value Share Analysis, by Country, 2016 and 2024
Figure 29: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 30: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 31: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 32: Europe Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 33: Europe Market Attractiveness Analysis, by Country, 2015
Figure 34: Europe Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 35: Europe Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 36: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 37: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 38: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 39: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Asia Pacific Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 41: Asia Pacific Market Attractiveness Analysis, by Country, 2015
Figure 42: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 43: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 44: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 45: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 46: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 47: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 48: Latin America Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 49: Latin America Market Attractiveness Analysis, by Country, 2015
Figure 50: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 51: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 52: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 53: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 54: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 55: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 56: Middle East & Africa Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 57: Middle East & Africa Market Attractiveness Analysis, by Country, 2015
Figure 58: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 59: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 60: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 61: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 62: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 63: Global Skin Biopsy Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 64: Global Imaging Techniques Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 65: Global Prostacyclin Analogues Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 66: Global Electrocardiogram & Echocardiogram Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 67: Global Pulmonary Function Tests Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 68: Global Scleroderma Diagnostics Market Attractiveness Analysis, by Test Type, 2015
Figure 69: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes